July 2008 Br J Cardiol 2008;15:210-14
Michael O’Reilly, Ulrike Hostalek, John Kastelein
Introduction Cardiovascular events remain the leading cause of morbidity and mortality in developed countries, and the treatment of dyslipidaemia is central to the overall management of cardiovascular risk.1,2Although correction of hypercholesterolaemia remains the principal target for correction of the lipid profile, dyslipidaemia is heterogeneous in presentation, with many patients presenting with low high-density lipoprotein-cholesterol (HDL-C) in addition to elevated concentrations of ApoB-containing lipoproteins. A survey carried out in 11 European countries identified low HDL-C (<1.03 mmol/L in men and <1.29 mmol/L in women) in ab
March 2008 Br J Cardiol 2008;15:65-6
Sarah Jarvis
The struggle to meet targets GPs are struggling to meet these targets, with only 56–59% of patients achieving HbA1c <7.5% in at least 50% of patients in 2004/5, and 59–62% of patients in 2005/6.6 While metformin has an excellent safety and efficacy record, and continues to be standard first-line therapy for all patients who can tolerate it, UKPDS has shown us that for most patients, multiple hypoglycaemic agents are necessary. Sulphonylureas are also well tried and tested, and relatively cheap, but carry the risk of weight gain and hypoglycaemia, especially with longer-acting versions such as chlorpropamide and glibenclamide. In additi
November 2006 Br J Cardiol 2006;13:411-8
BJCardio editorial team
No content available
September 2006 Br J Cardiol 2006;13:347-50
Clive Weston, Achanthodi Vasudev, Daniel Obaid, Saatehi Bandhopadhay, Jiten Vora
No content available
March 2005 Br J Cardiol (Acute Interv Cardiol) 2006;13:AIC 14–AIC 18
Kausik Ray, James Bolton, Alice Veitch, Paul Sheridan, Michael Gillett, Ahmed Al Rifai, Ramasamy ManivArmane, Alan Brennan, Gillian Payne, Wazir Baig
No content available
November 2003 Br J Cardiol 2003;10:472-7
Peter Tyerman, Gill V Tyerman, Trefor Roscoe, Mike Campbell, Jenny Freemen
No content available
July 2003 Br J Cardiol 2003;10:310-4
Mike Mead
No content available
July 2003 Br J Cardiol 2003;10:288-92
COX-2 inhibitors and cardiovascular risk Mike Schachter
No content available
July 2003 Br J Cardiol 2003;10:281-6
Jenny Poulter, Caroline Bolton-Smith, Anton Rietveld
No content available
March 2003 Br J Cardiol 2003;10:118-22
Jennifer Bexley
No content available
For healthcare professionals only
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits
